Nasdaq ardx.
ARDELYX INC ( ARDX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 100% based on the firm’s underlying fundamentals and the stock’s ...
May 18, 2023 · Q1 net loss was $26.8 million, but Ardelyx raised $51.9 million through sales of their common stock at an average price of about $3.35, leaving $130.4 million in total cash and investments as of ... Ardelyx Inc (NASDAQ:ARDX) trade information. Ardelyx Inc (ARDX) registered a 3.20% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 3.20% in intraday trading to $4.51 this Thursday, 11/30/23, hitting a weekly high. The stock’s 5-day price performance is 4.64%, and it has moved by 14.18% in 30 days.The latest price target for Ardelyx ( NASDAQ: ARDX) was reported by HC Wainwright & Co. on Wednesday, November 1, 2023. The analyst firm set a price target for 11.00 expecting ARDX to rise to ...Xencor Inc. 18.74. +0.01. +0.05%. Get Ardelyx Inc (ARDX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Ardelyx Inc. ARDX (U.S.: Nasdaq). AT CLOSE 4:00 PM EST 12/01/23. $4.76USD; 0.25 ... ARDX. Significant News Only. 11/17/22; Barron's. Ardelyx Skyrockets. Its ...
Complete Ardelyx Inc. stock information by Barron's. View real-time ARDX stock price and news, along with industry-best analysis.
The FDA approved Ardelyx Inc's (NASDAQ:ARDX) Xphozah (tenapanor), the first and only phosphate absorption inhibitor, indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD ...
WALTHAM, Mass., Feb. 2, 2023 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that on January 27, 2023, the compensation committee of the company's …Ardelyx, Inc. (NASDAQ:ARDX) Q3 2023 Earnings Call Transcript (Insider Monkey) Oct-31-23 11:15PM Q3 2023 Ardelyx Inc Earnings Call (Thomson Reuters StreetEvents) +9.12%. 05:09PM Why Ardelyx Stock Soared Today (Motley Fool) 08:40AM Ardelyx (ARDX) Q3 Earnings and Revenues Top Estimates ...Get the latest FibroGen Inc (FGEN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Get Ardelyx Inc. (ARDX) share price today and stock analysis, price valuation, performance, fundamentals, market cap, shareholding, financial report, etc.
Ardelyx, Inc. (NASDAQ:ARDX) focuses on treatments for gastrointestinal system and kidney diseases. Its latest analyst share coverage came from Cantor Fitzgerald which upgraded the share rating to ...
Aug 26, 2023 · Ardelyx (NASDAQ:ARDX) is a biotechnology company that focuses on developing novel therapies for unmet medical needs. The company’s growth and potential breakthroughs in medical treatments could ...
NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end-of-month settlement dates. It is then ...Ardelyx, Inc. ( NASDAQ:ARDX) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally.Ardelyx Stock (NASDAQ:ARDX), Short Interest Report. Short interest for Ardelyx gives investors a sense of the degree to which investors are betting on the decline of Ardelyx's stock.Ardelyx (NASDAQ:ARDX) is a great speculative biotech play to look into. Why is that? That's because despite its potential with two drugs in the pipeline, the stock is still trading with a very low ...FREMONT, Calif., Aug. 3, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment ...Ardelyx has generated ($0.12) earnings per share over the last year ( ($0.12) diluted earnings per share). Earnings for Ardelyx are expected to grow in the coming year, from ($0.31) to ($0.24) per share. Ardelyx has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 7th, 2024 ...
WALTHAM, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...Dec 29, 2022 · Ardelyx, Inc. (NASDAQ:ARDX) is a Waltham, Massachusetts-based biopharmaceutical company focused on the development of first-in-class remedies that meet significant unmet medical needs. Oct 11, 2023 · Shares of Ardelyx ( ARDX 3.20%) were down more than 12% as of 3:30 p.m. on Wednesday. The healthcare company, which has a chronic kidney disease (CKD) drug that is awaiting approval later this ... Shares of Ardelyx (NASDAQ: ARDX) were up 13.2% as of 2:30 p.m. ET Wednesday after the U.S. Food and Drug Administration (FDA) approved its first-in-class chronic kidney disease drug. In a press ...Stock analysis for Ardelyx Inc (ARDX:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Oct 31, 2023 · Shares of Ardelyx (NASDAQ: ARDX) were up 9.5% as of 3:47 p.m. after the biotech company announced better-than-expected third-quarter 2023 results. WALTHAM, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...
Massachusetts-based Ardelyx (NASDAQ:ARDX) is another hot biotech to consider heading into 2023. All after the US FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted in favor of ...
The put contract at the $4.00 strike price has a current bid of 15 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $4.00, but will also ...Ardelyx Inc (NASDAQ:ARDX) trade information. Upright in the red during last session for losing -0.39%, in the last five days ARDX remained trading in the green while hitting it’s week-highest on Wednesday, 11/15/23 when the stock touched $3.86 price level, adding 6.76% to its value on the day.NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...Ardelyx, Inc. (NASDAQ:ARDX) BioNTech SE (NASDAQ:BNTX) Globus Medical, Inc. (NYSE:GMED) GW Pharmaceuticals plc (NASDAQ:GWPH) Medpace Holdings, Inc. (NASDAQ:MEDP) ... Qorvo (NASDAQ:QRVO) said the ...Find the latest dividend history for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com. Ardelyx Inc (NASDAQ:ARDX) trade information. Ardelyx Inc (ARDX) registered a 3.20% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 3.20% in intraday trading to $4.51 this Thursday, 11/30/23, hitting a weekly high. The stock’s 5-day price performance is 4.64%, and it has moved by 14.18% in 30 days.Ardelyx has generated ($0.12) earnings per share over the last year ( ($0.12) diluted earnings per share). Earnings for Ardelyx are expected to grow in the coming year, from ($0.31) to ($0.24) per share. Ardelyx has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 7th, 2024 ...May 17, 2023 · Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical ... Stock analysis for Ardelyx Inc (ARDX:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Ardelyx, Inc. (NASDAQ:ARDX) has gained about 353% over the past 12 months. As of the end of the first quarter of 2023, 20 hedge funds tracked by Insider Monkey were long Ardelyx, Inc. (NASDAQ:ARDX ...
Shares of Ardelyx (NASDAQ: ARDX) were up 9.5% as of 3:47 p.m. after the biotech company announced better-than-expected third-quarter 2023 results.
WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...
A total of 14 hedge funds in Insider Monkey’s database of hedge funds had stakes in Ardelyx Inc. (NASDAQ:ARDX). The most significant stake in Ardelyx Inc. (NASDAQ:ARDX) was owned by. 6.WALTHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Ardelyx (NASDAQ:ARDX – Get Free Report)‘s stock had its “outperform” rating reiterated by investment analysts at Wedbush in a report released on Friday, Benzinga reports. They currently have a $9.00 price objective on the biopharmaceutical company’s stock. Wedbush’s price objective would suggest a potential upside of 89.08% from the company’s previous close. Several other ...WALTHAM, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has approved Xphozah …WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...Ardelyx, Inc. Common Stock (ARDX). Nasdaq Listed ...Analysts have provided the following ratings for Ardelyx (NASDAQ:ARDX) within the last quarter: According to 5 analyst offering 12-month price targets in the last 3 months, Ardelyx has an average ...WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Analysts' Revenue Estimates For Ardelyx, Inc. (NASDAQ:ARDX) Are Surging Higher Dec 02. Ardelyx Announces Launching of IBSRELA® Second Quarter of 2022 Dec 01. Insider notifies of intention to sell stock Nov 19. Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.20 loss in 3Q 2020)Ardelyx, Inc. (NASDAQ:ARDX) is a Waltham, Massachusetts-based biopharmaceutical company focused on the development of first-in-class remedies that meet significant unmet medical needs.
Ardelyx, Inc. (NASDAQ:ARDX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts.The analysts have sharply increased their revenue ...Massachusetts-based Ardelyx (NASDAQ:ARDX) is another hot biotech to consider heading into 2023. All after the US FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted in favor of ...XPeng Inc. American depositary shares, each representing two Class A ordinary shares (XPEV) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global ...Ardelyx (ARDX) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.31 per share a year ago. These figures are ...Instagram:https://instagram. roth ira vs high yield savingscheapest low mileage car insurancerefinance with wells fargomatell stock Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor for adult patients with CKD on dialysis with hyperphosphatemia. The company will host a conference call on December 29, 2022, at 8:00 AM ET. To participate in the conference call, please call (866) 374-5140 (toll-free) or (404) 400-0571 (toll) and … what etf to buy nowbigltos Private Advisor Group LLC bought a new stake in shares of Ardelyx, Inc. ( NASDAQ:ARDX – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and ... west frazier WALTHAM, Mass., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end-of-month settlement dates. It is then ...